To sum up, YTHDF3 has the potential to become a novel therapeutic target for AAA due to its modulation of macrophages polarization and the restoration of the M1 phenotype/M2 phenotype ratio at the site of AAA. The gene discussed is YTHDF3; the disease is triple-A syndrome.